Philosophy of Care
Dr. Rolder admires the courage and fortitude that her cancer patients show on a daily basis and tries to help them through this difficult period. She researches all available treatment options and advise each patient as she would a family member. Her goal is to provide my patients with clear information in understandable language, and then to partner with them to decide which is the best treatment for them. She is a strong advocate for her patients and promise to support them during each stage of their cancer care.
Dr. Rodler is a clinician investigator in both breast cancer and sarcoma.
Dr. Rodler’s research interests are in triple negative breast cancer treatment. She specializes in breast cancer clinical care and research. Her area of research interest in is hormone receptor negative, HER2/neu negative breast cancer ("Triple negative breast cancer").
She is the principal investigator for a phase I clinical trial in patients with metastatic triple negative breast cancer which is exploring the efficacy of using a chemotherapy drug combination that causes DNA damage, and a new drug called a “PARP inhibitor” which acts as a double hit to these tumor cells. Poly (ADP-ribose) polymerase (PARP) inhibitors inhibit DNA repair in cancer cells that have pre-existing DNA repair defects, but not normal cells.
Hematology and Oncology
M.D., George Washington School of Medicine, District of Columbia, 1997
M.A., Yale University, New Haven, CT, 1983
B.A., Stanford University, Stanford, CA, 1981
Internal Medicine, UCLA Medical Center, Los Angeles, CA, 1998-2000
Hematology/Oncology, UC Davis Medical Center, Sacramento, CA, 2000-04
American Board of Hematology,
American Board of Medical Oncology,
American Society of Clinical Oncology
Physicians for a National Health Program
Southwest Oncology Group
Select Recent Publications
For a comprehensive list of Dr. Rodler's publications, please click here.